Australia offers a range of advantages for clinical trial sponsors. These include a well-established regulatory framework, fast study start-up times, access to a highly skilled workforce, and a diverse patient population. Importantly, the Australian Therapeutic Goods Administration (TGA) allows early-phase trials to start quickly under the Clinical Trial Notification (CTN) scheme without requiring pre-approval, significantly accelerating timelines.

Yes, clinical trial data from Australia is highly regarded and accepted by international regulatory agencies, including the U.S. Food and Drug Administration (FDA). Australian clinical trials adhere to ICH-GCP guidelines, ensuring the quality and integrity of the data meet global standards.

Yes, Linear is experienced in handling and shipping biological samples internationally. We comply with international shipping standards and manage the logistics to ensure sample integrity is maintained throughout the process. This includes using appropriate packaging, temperature controls, and expedited shipping services to meet regulatory and research timelines.

To obtain a CTN acknowledgment, sponsors submit the necessary trial documentation to the TGA via an online portal. The sponsor must ensure that the trial is ethically approved by a Human Research Ethics Committee (HREC) before submitting the CTN. Once submitted, the TGA acknowledges the notification, typically within days, allowing the trial to commence without further regulatory delays​.

The R&D Tax Incentive in Australia offers generous rebates to companies conducting research and development activities. Eligible clinical trial sponsors can claim up to 43.5% of their R&D expenditure as a refundable tax offset. This incentive helps reduce the financial burden of running trials and encourages sponsors to invest in innovative research within Australia​.